Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Matterhorn Biosciences

Request full access

Develops T cell receptor therapies targeting cancer through MR1T cell technology

Basel, SwitzerlandFounded 2019Biotech & Life Sciences

About Matterhorn Biosciences

Matterhorn Biosciences GmbH, founded in 2019 by leading scientists from the University of Basel and Versant Ventures, specializes in pioneering MR1T cell therapies for cancer treatment. The company operates in the biotechnology sector, focusing on adoptive cell therapy to target MR1 presented antigens across a broad range of cancers. Matterhorn's MR1T cells are designed to selectively kill cancer cells while sparing healthy tissues, addressing both liquid and solid tumors. The business model revolves around developing and commercializing these advanced therapies, collaborating closely with academic institutions like the University of Basel and Ridgeline to maintain leadership in MR1 directed cancer cell therapy. Revenue is generated through partnerships, licensing agreements, and potentially direct sales of their therapeutic products. The primary clients include healthcare providers, research institutions, and pharmaceutical companies seeking innovative cancer treatment solutions.

Source: Dealroom company data

At a glance

Status
Closed
Employees
6
Open positions
None listed
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Spinout, Cell Therapy, Woman Founder, DT and LS, science-based, Swiss DT Biotech
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Aug 2020 $30M $120M Versant Ventures ↗
SPINOUT✓Other financing May 2019 $0 — University of Basel ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Matterhorn Biosciences website traffic

Latest recorded traffic for Matterhorn Biosciences is 200 monthly website visits, down 23.1% over the last three months. Matterhorn Biosciences's team grew 0% over the past year.

Latest monthly visits200 3-month web change-23.1% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Matterhorn Biosciences in the Basel ecosystem

Live from Dealroom

The Matterhorn Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

Other known investors1 additional known investor

  • University of Basel
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇭 Switzerland · Basel HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Matterhorn Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Matterhorn Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.